Vaishali Pharma Limited

VAISHALI

INE972X01014

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 05:13:55 03/07/2024 pm IST			5-day change	1st Jan Change
154.3 ^INR	-0.43%		-4.18%	-15.19%

30/05	Vaishali Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
02/02	Vaishali Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Vaishali Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2020

September 15, 2020 at 05:07 pm IST

Vaishali Pharma Limited announced earnings results for the first quarter ended June 30, 2020. For the first quarter, the company announced total revenue was INR 41.08 million compared to INR 182.06 million a year ago. Net income was INR 0.023 million compared to INR 0.059 million a year ago. Basic earnings per share from continuing operations was INR 0.01 compared to INR 0.01 a year ago.

Latest news about Vaishali Pharma Limited

Vaishali Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	30/05	CI
Vaishali Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02/02	CI
Vaishali Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11	CI
Vaishali Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	07/23/07	CI
Vaishali Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	22/23/22	CI
Vaishali Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	06/23/06	CI
Vaishali Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	03/22/03	CI
Vaishali Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	25/22/25	CI
Vaishali Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022	30/22/30	CI
Vaishali Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	21/22/21	CI
Vaishali Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	10/21/10	CI
Vaishali Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	24/21/24	CI
Vaishali Pharma Limited Receives Supply Orders in Excess of USD 100,000 from Russia	22/21/22	CI
Vaishali Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	14/21/14	CI
Vaishali Pharma Limited Receives an Order Worth USD 270,000	22/21/22	CI
Vaishali Pharma Limited Initiates 30 Products Registration in Central African Countries	16/21/16	CI
Vaishali Pharma Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	19/21/19	CI
Vaishali Pharma Limited Receives Another Bulk Order Worth INR 320 Million of PPE KITS	14/21/14	CI
Vaishali Pharma Limited Enters into In-Licensing Agreement for the U.S.A Market	04/21/04	CI
Vaishali Pharma Limited Provides Updates on the Major Bulk Order of INR 160 Million for PPE Kits & Covid -19 Medical Kits	01/21/01	CI
Vaishali Pharma : Secures over $2 Million Bulk Order for PPEs and COVID-19 Related Products; Shares Soar 10%	30/20/30	MT
Vaishali Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	15/20/15	CI
1,325,000 Equity Shares of Vaishali Pharma Limited are subject to a Lock-Up Agreement Ending on 31-AUG-2020.	31/20/31	CI
Vaishali Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2020	30/20/30	CI
Vaishali Pharma Launches Vipravita C (Immunity Booster Vitamin C Supplements)	14/20/14	CI

Chart Vaishali Pharma Limited

Duration

Period

More charts

Company Profile

Vaishali Pharma Limited is an India-based pharmaceutical company. The Company is engaged in dealing in pharmaceutical ingredient, pharmaceutical formulations, surgical products, herbal and nutraceutical products, veterinary supplements operating in domestic and export market. Its product categories include active pharmaceutical ingredients (APIs), formulation brands, formulations, herbal, nutraceuticals, oncology, surgical and veterinary, among others. It offers APIs, including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The Company markets approximately 1,500 products and has more than 200 brands, around 35 countries.

Sector

Pharmaceuticals

Calendar

22/07/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VAISHALI PHARMA LIMITED	-15.19%	1.99Cr
ELI LILLY AND COMPANY	+55.55%	82TCr
NOVO NORDISK A/S	+39.65%	63TCr
JOHNSON & JOHNSON	-6.83%	35TCr
MERCK & CO., INC.	+17.15%	32TCr
ABBVIE INC.	+7.09%	29TCr
ASTRAZENECA PLC	+13.30%	24TCr
ROCHE HOLDING AG	+0.82%	22TCr
NOVARTIS AG	+13.48%	22TCr
AMGEN INC.	+7.87%	17TCr